Saito Biomedical: Subsidiary Dexamethasone Active Pharmaceutical Ingredient (API) Listing Application Approved

Cytovance Biologics announced that its holding subsidiary Shandong Sray Pharmaceutical recently received the approval notice for the listing application of dexamethasone active pharmaceutical ingredient (API). The API meets the requirements for drug registration and has been approved for registration. Dexamethasone is a long-acting glucocorticoid drug. Its approval will enrich the company's product line and enhance market competitiveness. Currently, the API is not yet being sold, and the production and sales time is affected by factors such as the progress of GMP compliance inspection and market environment, leading to uncertainties. The global consumption of dexamethasone API is nearly 9 tons in 2024. The sales of the drug are influenced by internal and external factors, so investors need to be aware of the risks.